CMS Lacks Authority To Exempt Part B Drugs From Sequester Cuts – Tavenner
This article was originally published in The Pink Sheet Daily
Executive Summary
“We do not believe that we have the authority under the Budget Control Act of 2011 to exempt Medicare payment for Part B drugs,” CMS Administrator Marilyn Tavenner told members of Congress in a June 3 letter.
You may also be interested in...
Oncology Groups Ask HHS To Revise How Sequester’s Cuts Are Applied To Part B Drugs
A 2% cut is being applied first to the average sales price for drugs reimbursed by Medicare Part B, and then another 2% is taken out of the 6% add-on. The approach compounds the overall reduction to a level that far exceeds the 2% Medicare cut required by sequestration, according to the groups.
Xtandi Pricing and Patents: Alternatives To March-In Urged To Lower Medicare, Medicaid Costs
The timing of the request, with Xtandi’s loss of exclusivity on the horizon, could be explained by the concern that a change in the US presidential administration in 2025 may limit the prospects for near-term relief.
Medicare-Negotiated Drugs May Not Get Favorable Coverage In Part D: Will CMS Intervene?
Insurance plans put on notice that CMS is concerned about restrictions on drugs with negotiated prices, but it’s not clear what the agency can or will do about it.